BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38383739)

  • 1. Dynamic hydrogen peroxide levels reveal a rate-dependent sensitivity in B-cell lymphoma signaling.
    Witmond M; Keizer E; Kiffen B; Huck WTS; van Buggenum JAGL
    Sci Rep; 2024 Feb; 14(1):4265. PubMed ID: 38383739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
    Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
    Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.
    Bogusz AM; Baxter RH; Currie T; Sinha P; Sohani AR; Kutok JL; Rodig SJ
    Clin Cancer Res; 2012 Nov; 18(22):6122-35. PubMed ID: 22966017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
    Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
    Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
    Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
    Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid desensitization of B-cell receptor by a dithiol-reactive protein tyrosine phosphatase inhibitor: uncoupling of membrane IgM from syk inhibits signals leading to Ca2+ mobilization.
    Rozsnyay Z; Sarmay G; Gergely J
    Immunol Lett; 1995 Jan; 44(2-3):149-56. PubMed ID: 7541023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYC Protein-positive Diffuse Large B-Cell Lymphoma Features an Activated B-Cell Receptor Signal Pathway.
    Wang WG; Jiang XN; Liu ZB; Zhou XY; Li XQ
    Am J Surg Pathol; 2017 Apr; 41(4):541-549. PubMed ID: 28291124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
    Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
    Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
    Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
    Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
    Goldstein RL; Yang SN; Taldone T; Chang B; Gerecitano J; Elenitoba-Johnson K; Shaknovich R; Tam W; Leonard JP; Chiosis G; Cerchietti L; Melnick A
    J Clin Invest; 2015 Nov; 125(12):4559-71. PubMed ID: 26529251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
    Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
    Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
    Juszczynski P; Chen L; O'Donnell E; Polo JM; Ranuncolo SM; Dalla-Favera R; Melnick A; Shipp MA
    Blood; 2009 Dec; 114(26):5315-21. PubMed ID: 19855081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.
    Blix ES; Irish JM; Husebekk A; Delabie J; Forfang L; Tierens AM; Myklebust JH; Kolstad A
    BMC Cancer; 2012 Oct; 12():478. PubMed ID: 23072591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
    Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
    Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
    Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
    Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
    Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
    Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
    Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
    Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system.
    Akhter A; Masir N; Elyamany G; Phang KC; Mahe E; Al-Zahrani AM; Shabani-Rad MT; Stewart DA; Mansoor A
    J Neurooncol; 2015 Jan; 121(2):289-96. PubMed ID: 25391967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.